Moderna Falls After Reportedly Delaying Covid-19 Vaccine Trial

This post was originally published on this site

https://i-invdn-com.akamaized.net/news/LYNXNPEF102VH_M.jpg
© Reuters. © Reuters.

By Yasin Ebrahim

Investing.com – Moderna fell sharply Friday, as the drugmaker is reportedly delaying a clinical trial for its Covid-19 vaccine candidate. 

Moderna (NASDAQ:) fell 5%.

In a blow to the company’s expectations to roll out key data from its coronavirus vaccine by Thanksgiving, Moderna’s 30,000-patient trial of its coronavirus vaccine candidate, expected to start next week, has been delayed following changes to the protocol, Statnews reported.

The trial could still get underway in July as the company looks “close to being on target,” Statnews said, citing one investigator.

“My understanding was that they wanted to get the first vaccines given in July, and they say they’re still committed to do that,” one investigator said. “As best I can tell, they’re close to being on target for that.”

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Add Comment